通过阿托瓦昆诱导的PERK/eIF2α信号轴的激活会减轻代谢性辐射敏感化
Jie Feng1, Varun Pathak2, Niall M Byrne1
1School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, Northern Ireland, UK.
Cell communication and signaling : CCS
|April 2, 2025
概括
阿托瓦昆破坏了瘤细胞的呼吸,最初使癌细胞对辐射敏感. 然而,它会触发一种适应性应激反应,从而产生抗性,从而限制其有效性. 抑制这种应激反应可以恢复atovaquone的功能.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 缺氧是头癌放射治疗的一个主要挑战,通过诱导辐射耐药性来降低治疗效率.
- 作为线粒体抑制剂的阿托瓦昆在降低瘤缺氧方面表现出潜力,但其放射敏感化作用不一致.
- 一个涉及综合应激反应 (ISR) 信号的适应性抵抗机制限制了atovaquone在头部和部状细胞癌 (HNSCC) 的放射敏感化潜力.
研究的目的:
- 在HNSCC模型中研究阿托瓦昆对低氧反应的影响.
- 揭示综合应激响应 (ISR) 信号传导在调解对阿托瓦奎介导的辐射敏感化耐药性的作用.
- 探索克服阿托瓦克引起的放射电阻的策略.
主要方法:
- 使用海马XFe96分析仪评估生物能量反应.
- 通过克隆原生存活试验和ROS产量分析评估了辐射敏感化效应.
- 研究ISR信号激活及其在辐射敏感性中的作用,使用西式涂抹,qRT-PCR,siRNA和eIF2α的药理抑制.
主要成果:
- 阿托瓦昆破坏了线粒体呼吸,并通过eIF2α酸化触发了ISR激活.
- 在使用阿托瓦昆的低氧条件下,自增强;自抑制增强了亡和放射敏感性.
- 联合eIF2α抑制和atovaquone增强了ROS的产生,并恢复了放射性敏感性.
结论:
- 阿托瓦昆具有双重效应:通过OXPHOS抑制进行放射敏感化,并通过ISR信号传递进行放射电阻.
- 阻碍ISR激活可以恢复atovaquone的放射敏感性.
- 针对ISR信号提供了一种新的策略,以抵消HNSCC中缺氧诱导的放射电阻.
更多相关视频
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
738
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.4K
相关概念视频
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Intrinsic Apoptotic Pathway
5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Unfolded Protein Response
4.3K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.3K
